Clinical Trials Logo

Filter by:
NCT ID: NCT05830136 Recruiting - Hepatic Ischemia Clinical Trials

Application of Sodium Bicarbonate Ringer's Solution in Laparoscopic Hepatectomy

Start date: February 1, 2022
Phase: N/A
Study type: Interventional

Compared the effects of Sodium bicarbonate Ringer's solution and lactate Ringer's solution on the internal environment and hemodynamics of patients during laparoscopic liver resection, to observe the application prospect of sodium bicarbonate Ringer's solution in Laparoscopic hepatectomy.

NCT ID: NCT05830123 Recruiting - Sarcoma Clinical Trials

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Start date: June 8, 2023
Phase: Phase 2
Study type: Interventional

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with relapsed or refractory osteosarcoma and other sarcomas.

NCT ID: NCT05830097 Recruiting - Cancer, Breast Clinical Trials

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

Start date: March 14, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1019, a bi-specific ligand conjugated drugs in patients with advanced solid tumors.

NCT ID: NCT05830019 Recruiting - Clinical trials for Pancreatic Carcinoma

Carbon Ion Radiotherapy for Recurrent Pancreatic Cancer Post Surgery

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the toxicity and tolerance of carbon ion radiotherapy for recurrent pancreatic carcinoma post surgery

NCT ID: NCT05829746 Recruiting - Clinical trials for Cardiovascular Diseases

PROSPECTIVE, MULTI-CENTER, OPEN-LABEL, SINGLE-ARM REGISTRATION TRIAL OF THE TUBRIDGE FOR THE TREATMENT OF WIDE-NECKED SMALL AND MEDIUM-SIZED INTRACRANIAL ANEURYSMS

Start date: November 3, 2022
Phase: N/A
Study type: Interventional

A trial to evaluate the safety and efficacy of the Tubridge flow-diverter stent for the treatment of intracranial wide-necked, small to medium-sized aneurysms.

NCT ID: NCT05829720 Recruiting - Clinical trials for Digestive System Disease

Investigate Effects of a2 Milk on Breastmilk Composition and Subsequent Infant Gut Health, Crying and Sleep Patterns in Healthy, Full-term Infants

Start date: June 17, 2024
Phase: N/A
Study type: Interventional

The goal of this interventional study is to investigate effects of a2 Full Cream Milk on Breastmilk composition and subsequent Infant gut health, crying frequency and sleep patterns in Healthy Full-term Infants. 50 mothers and thier infants will be enrolled into 2 study sites, mother and her child as one subject will be randomized to 2 groups for assigned interventions, a2 Full Cream Milk and conventional Milk (Weidendorf). The study will continue for 14 days, and 3 site visits will be made duing the study period. All data specified in the protocol will be captured and recorded into CTMS for analysis. Researchers will compare the two groups of participants to see if a2 Full Cream Milk has significantly better breastmilk composition and improve infant's gut health, crying frequency and sleep patterns.

NCT ID: NCT05829213 Recruiting - Anastomosis Clinical Trials

A Modified Esophagogastric Reconstruction Method After Laparoscopic Proximal Gastrectomy

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

The double-flap technique (DFT) is an effective digestive tract reconstruction method after proximal gastrectomy (PG) to reduce the incidence of postoperative reflux esophagitis. But its clinical application is restricted due to the technical complexity. Our surgical team devise a modified esophagogastric reconstructive method which we term the "arch-bridge-type" reconstruction based on the principle of DFT. The aim of this single-arm prospective study is to assess the safety and feasibility of the "arch-bridge-type" reconstruction after PG.

NCT ID: NCT05829122 Recruiting - Aphakia Clinical Trials

Sutureless Intrascleral Intraocular Lens Fixation and Modified Iris Cerclage Pupilloplasty

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

In this study, patients with various causes of pupillary dilatation were recruited, and medical records and ophthalmology examinations, including slit-lamp examination, visual acuity, best corrected visual acuity, intraocular pressure, pupil diameter, corneal endothelial cell count, fundus examination, and photophobia score, were collected. Those who met the recruitment criteria underwent modified iris cerclage pupilloplasty. The modified iris cerclage pupilloplasty was performed by making four clear corneal incisions, suturing the iris 3-4 times consecutively between each two incisions, completing 360 degrees of iris suturing in sequence, and finally tying the knot intraocularly to complete the iris cerclage.

NCT ID: NCT05829057 Recruiting - Ovarian Cancer Clinical Trials

The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1

Start date: May 23, 2023
Phase: Phase 1
Study type: Interventional

Phase Ia: single-dose escalation study: accelerated titration combined with traditional "3+3" dose. Sample size is correlated with the DLT occurring in each dose group. 4 dose groups are expected; the first dose group is the accelerated titration group, which includes only 1 subject; subsequent dose groups are in traditional "3+3" dose increments, with 3-6 subjects in each group; a total of 10-19 subjects are expected in all dose groups. If the DLT is still not present in the highest dose ,the safety monitoring committee(SMC) to determine if it is necessary to continue incrementally to a higher dose.

NCT ID: NCT05828953 Recruiting - Clinical trials for Interstitial Lung Diseases

Anlotinib Capsules in the Treatment for IPF/PF-ILDs

Start date: September 28, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The use of Anlotinib hydrochloride capsules for the treatment of IPF/PF-ILDs, with FVC as the primary efficacy endpoint to evaluate its effectivenes